The widening loss is concerning, but the $76.9M cash runway supports ongoing clinical and commercial development. Traders should monitor upcoming milestones: completion of U.S. skin cancer trial recruitment (Q1 2026), pancreatic trial enrollment (Q2 2026), and initial GBM safety readout (Q2 2026). Positive data or accelerated approvals could drive upside.
DRTS drugs
DRTS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 10 $6.84entry
- T+1 · 8mo ago +2.92%α +3.03% · $7.04
- T+5 · 8mo ago +9.21%α +10.12% · $7.47
- T+20 · 7mo ago +5.26%α +5.42% · $7.20
- T+60 · 6mo ago +54.68%α +42.99% · $10.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical reported its 2025 financial results, showing a wider net loss of $42.6 million ($0.53/share) compared to $31.8 million ($0.45/share) in 2024, driven by higher R&D and G&A expenses. Despite the increased loss, the company highlighted significant clinical and regulatory progress, including Japanese marketing approval for head and neck cancer, five U.S. trial approvals, and positive pancreatic cancer data presented at ASCO GI, while ending the year with $76.9 million in cash.
Key Financial Metrics
Key Facts
- Net loss widened to $42.6M in 2025 from $31.8M in 2024
- R&D expenses increased to $32.1M from $27.0M in 2024
- Cash, cash equivalents, and deposits totaled $76.9M as of Dec 31, 2025
- Received marketing approval in Japan for head and neck cancer
- Five U.S. clinical trials approved in parallel, including for prostate and brain cancers
- Positive pancreatic cancer data: 22% ORR and 81% DCR in 32-patient study
- First patient treated in U.S. recurrent glioblastoma trial
- Submitted first module of PMA application to FDA for skin cancer
Financial Impact
Net loss increased by 34% YoY to $42.6 million; cash position grew by $14 million to $76.9 million
Risk Factors
- Continued losses and need for future funding could lead to dilution
- Clinical trial delays or adverse results could impair development timelines
- Regulatory setbacks in U.S. or other markets despite Japanese approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252290 |
Track record
25 reports on DRTS
9 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers